Westerhof W, Kooyers TJ
Wegovy, however, has a longer clinical track record, more published long-term safety data, and the unique cardiovascular risk reduction approval
Patients lost an average of 9.81 kg (about 21.6 lbs) compared to placebo, with even higher reductions at higher doses. Weight loss increased with higher doses (5 mg, 10 mg, and 15 mg) demonstrating a clear dose-response relationship. More participants achieved at least 5%, 10%, and 15% body weight reductions compared to those on placebo or other diabetes medications. Mounjaro has a unique approach to weight loss, as it targets two key pathways in the body
With IV infusion, your body absorbs nearly 100% of the vitamin, meaning you feel the benefits almost immediately
More research is needed on how semaglutide affects testosterone, but Kohn says he doesnt see a big effect in practice